Cereblon expression in multiple myeloma: Not ready for prime time

British Journal of Haematology

Volumn 163, Issue 2, 2013, Pages 282-284

  Lodé, Laurence ^a   Amiot, Martine ^b   Maiga, Sophie ^b   Touzeau, Cyrille ^a,b   Menard, Audrey ^a   Magrangeas, Florence ^a,b   Minvielle, Stephane ^a,b   Pellat Deceunynck, Catherine ^b   Bene, Marie Christine ^a   Moreau, Philippe ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Drug resistance; Multiple myeloma; Prognostic factors

Indexed keywords

BETA CATENIN; CEREBLON; CHROMOSOME PROTEIN; DEXAMETHASONE; LENALIDOMIDE; MESSENGER RNA; SYNDECAN 1; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL POPULATION; CELL SELECTION; CORRELATION ANALYSIS; DIPLOIDY; DRUG TARGETING; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; MULTIPLE MYELOMA; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TRISOMY;

DRUG RESISTANCE; MULTIPLE MYELOMA; PROGNOSTIC FACTORS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84884979674     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12478     Document Type: Letter

References (8)

1. Broyl, A., Kuiper, R., van Duin, M., van der Holt, B., El Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H.M., Goldschmidt, H. & Sonneveld, P. (2012) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood, 124, 624-627.
2. + multiple Myeloma Cells. Blood (ASH Annual Meeting Abstracts), 120 (Suppl. 1), 4043.
3. Heintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U. & Palumbo, A. (2013) High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. British Journal of Haematology, 161, 695-700.
4. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science, 327, 1345-1350.
5. Kumar, S., Fonseca, R., Ketterling, R.P., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., Hayman, S.R., Buadi, F.K., Dingli, D., Knudson, R.A., Greenberg, A., Russell, S.J., Zeldenrust, S.R., Lust, J.A., Kyle, R.A., Bergsagel, L. & Rajkumar, S.V. (2012) Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 119, 2100-2105.
6. Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. & Chopra, R. (2012) Cereblon is a direct protein target for immunomo-dulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26, 2326-2335.
7. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. & Shaughnessy, J.D. Jr. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020-2028.
8. Zhu, X.Y., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.